What it is
Selank is a peptide, a short chain of amino acids (the building blocks of proteins). It has seven: threonine, lysine, proline, arginine, proline, glycine, proline. It is made in a laboratory and does not occur naturally.
More on what it is and where it came from
Its first four amino acids are tuftsin, a natural peptide cut from part of the body's antibodies (immunoglobulin G) that stimulates certain immune cells. The last three, Pro-Gly-Pro, were added so the molecule is broken down more slowly.
Russian researchers describe it as an anxiolytic, meaning a drug that reduces anxiety. Outside Russia it is sold online as a research chemical, and a Belgian medicines laboratory has found it in seized, unlabelled preparations.
Selank was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences in Moscow, working with the V.V. Zakusov Research Institute of Pharmacology. Under the code name TP-7 it was being tested in rats by the mid-1990s. Most of the later animal and human research comes from the same Moscow institutes and the Mental Health Research Center.
How it is thought to work
Nobody has shown how selank works in people. Two main ideas come from laboratory and animal work by the developers' research network.
More on how it works
The first is the GABA system, the brain's main calming signal and the target of benzodiazepine tranquillisers. In laboratory binding tests selank increased the binding of GABA to its receptors, and in rats a single dose into the nose changed the activity of dozens of brain genes in a pattern partly resembling GABA. But in human nerve cells grown in a dish, selank on its own changed none of the genes measured.
The second is the body's own opioid-like peptides, the enkephalins. In test-tube experiments selank slowed the enzymes that break enkephalins down, and in one mouse strain it lengthened enkephalin's survival in the blood. Researchers have also reported effects on immune signalling molecules. These are hypotheses, not established mechanisms.
What is established in people
Very little is established in people. The patient studies found were three small Russian comparisons in anxiety disorders (62, 60 and 70 patients) against or alongside benzodiazepine tranquillisers, with no placebo group, and their abstracts do not describe randomisation, blinding or detailed side effects. They come from one research network linked to the developers and were published in Russian. A 2020 brain-scan study in 52 healthy volunteers measured scan patterns, not symptoms. No trial is registered on ClinicalTrials.gov and no independent trial outside Russia was found.
What the studies found
12 studies, human trials first. Each links to the paper or registry record.
- Human trial2020
Functional Connectomic Approach to Studying Selank and Semax Effects
The groups differed in how strongly the right amygdala (a brain area involved in fear and anxiety) was connected with parts of the right temporal lobe.
Full finding, who was studied, and limits
Who: 52 healthy volunteers given selank, semax (a related Russian peptide) or placebo, with brain scans (resting-state functional MRI) before and 5 and 20 minutes afterwards. Group sizes are not given in the abstract.
The groups differed in how strongly the right amygdala (a brain area involved in fear and anxiety) was connected with parts of the right temporal lobe. The authors described both shared and drug-specific effects.
Read with care: A short brain-scan study in healthy people. Changes in scan patterns do not show a clinical benefit. Route of administration, blinding and randomisation are not described in the abstract.
- Human trial2015
[Optimization of the treatment of anxiety disorders with selank]
Adding selank was reported to make phenazepam work sooner on a depression rating scale (HDRS), to reduce several of phenazepam's side effects during treatment and after it was stopped (including memory and attention problems, sedation, tiredness, sexual problems and dizziness on standing), and to improve quality of life.
Full finding, who was studied, and limits
Who: 70 patients with anxiety-phobic, hypochondriac and somatoform disorders: 30 given phenazepam alone and 40 given phenazepam plus selank.
Adding selank was reported to make phenazepam work sooner on a depression rating scale (HDRS), to reduce several of phenazepam's side effects during treatment and after it was stopped (including memory and attention problems, sedation, tiredness, sexual problems and dizziness on standing), and to improve quality of life.
Read with care: Small, open comparison with no placebo, unequal groups, and no description of randomisation or blinding in the abstract. One of the authors' affiliations is the Institute of Molecular Genetics, where selank was developed. Published in Russian.
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · pubmed.ncbi.nlm.nih.gov
- Human trial2014
[A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders]
The authors reported a clear anti-anxiety effect and a mild effect on thinking and memory, with better quality of life.
Full finding, who was studied, and limits
Who: 60 patients with phobic-anxiety and somatoform disorders (physical symptoms driven by anxiety), comparing selank with phenazepam, a benzodiazepine widely used in Russia. Group sizes are not given in the abstract.
The authors reported a clear anti-anxiety effect and a mild effect on thinking and memory, with better quality of life. They wrote that the anti-anxiety effect lasted about a week after treatment stopped.
Read with care: Small, no placebo, and the abstract does not describe randomisation, blinding, treatment length or specific side effects, even though tolerability was a stated aim. Published in Russian.
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · pubmed.ncbi.nlm.nih.gov
- Human trial2008
[Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia]
The authors reported that selank reduced anxiety about as much as medazepam on standard rating scales (Hamilton, Zung, Clinical Global Impression), and that it also had anti-fatigue and mildly stimulating effects.
Full finding, who was studied, and limits
Who: 62 patients with generalised anxiety disorder or neurasthenia (a diagnosis of persistent fatigue and nervous exhaustion): 30 given selank and 32 given medazepam, a benzodiazepine (Valium-type) tranquilliser.
The authors reported that selank reduced anxiety about as much as medazepam on standard rating scales (Hamilton, Zung, Clinical Global Impression), and that it also had anti-fatigue and mildly stimulating effects. Patients started with faster enkephalin breakdown in the blood, linked to how long and how severely they had been ill; selank slowed it.
Read with care: Small. No placebo group, so improvement cannot be separated from natural recovery or expectation. Randomisation and blinding are not described in the abstract. Treatment length and side effects are not reported in the abstract. Published in Russian by the developers' research network.
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · pubmed.ncbi.nlm.nih.gov
- Review2021
Sedative-Hypnotic Agents That Impact Gamma-Aminobutyric Acid Receptors: Focus on Flunitrazepam, Gamma-Hydroxybutyric Acid, Phenibut, and Selank
The authors described phenibut and selank as poorly studied Russian drugs acting on the GABA system that are sold to US consumers as dietary supplements, and called for their potential for misuse to be evaluated before such products reach the public.
Full finding, who was studied, and limits
Who: A review by pharmacists at the University of Connecticut and Hartford Hospital, USA.
The authors described phenibut and selank as poorly studied Russian drugs acting on the GABA system that are sold to US consumers as dietary supplements, and called for their potential for misuse to be evaluated before such products reach the public.
Read with care: A review, not new data. It is one of the few independent, non-Russian assessments found.
- Animal study2017
Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats
Under chronic stress, the combination of selank and diazepam brought anxiety measures back to pre-stress levels.
Full finding, who was studied, and limits
Who: Rats tested in a standard anxiety maze, with and without weeks of mild unpredictable stress, given selank, diazepam or both. Numbers are not given in the abstract.
Under chronic stress, the combination of selank and diazepam brought anxiety measures back to pre-stress levels. In rats that were not stressed, a course of either drug alone made anxiety measures worse, though less so with selank.
Read with care: Rats, and the developers' own institute. The finding that selank alone raised anxiety measures in unstressed rats is a reminder that effects are not simple or one-directional.
- Animal study2016
Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission
GABA is the brain's main calming chemical messenger.
Full finding, who was studied, and limits
Who: 30 male Wistar rats in three groups of ten (control, selank, GABA), given a single dose into the nose; brain tissue examined 1 and 3 hours later.
GABA is the brain's main calming chemical messenger. Of 77 genes analysed in the front of the brain, 45 changed activity at 1 hour and 22 at 3 hours. Changes at 1 hour after selank resembled those after GABA. The authors suggested selank may adjust the GABA system indirectly, and called for more research.
Read with care: Single doses in rats, with tissue pooled before analysis, which weakens the statistics. Gene activity changes do not show a benefit. The authors work at the institute that developed selank.
- Animal study2006
Influence of long-term treatment with tuftsin analogue TP-7 on the anxiety-phobic states and body weight
Anxiety-like behaviour fell from the second day of TP-7 treatment and stayed lower for the four weeks.
Full finding, who was studied, and limits
Who: 24 Wistar rats chosen for high anxiety, split into an untreated group, a vehicle-injection group and a TP-7 group, followed for four weeks.
Anxiety-like behaviour fell from the second day of TP-7 treatment and stayed lower for the four weeks. Body weight did not change.
Read with care: Small, and in rats. It is notable as one of the few studies from outside the Russian research network (Medical University of Lublin, Poland).
- Animal study1995
[The characteristics of the anxiolytic action of taftsin and its analog TP-7 on behavior and serotonin metabolism in the brain of rats with chronic deprivation of serotoninergic system activity]
Both peptides reduced signs of stress and steadied exploratory behaviour, and brought brain serotonin levels back towards normal.
Full finding, who was studied, and limits
Who: 95 adult male Wistar rats whose serotonin system had been damaged shortly after birth, given tuftsin or its analogue TP-7 (the early code name for selank).
Both peptides reduced signs of stress and steadied exploratory behaviour, and brought brain serotonin levels back towards normal. TP-7 had stronger anti-anxiety and stimulant effects than tuftsin itself.
Read with care: A rat model with artificial brain damage, from the developers' own research network. It shows early interest in the compound, not an effect in people.
Eksperimental'naia i klinicheskaia farmakologiia · pubmed.ncbi.nlm.nih.gov
- Cell study2018
Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity
Selank increased the binding of GABA to its receptors, which the authors describe as positive allosteric modulation (adjusting a receptor from a second site rather than switching it on directly).
Full finding, who was studied, and limits
Who: Brain membrane preparations tested in binding experiments (species not stated in the abstract).
Selank increased the binding of GABA to its receptors, which the authors describe as positive allosteric modulation (adjusting a receptor from a second site rather than switching it on directly). It also blocked the effects of diazepam and olanzapine in the same test.
Read with care: A laboratory binding test by the developing institute. It suggests a possible mechanism; it does not show an effect in people.
- Cell study2017
GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells
Selank on its own did not change the activity of any of the 84 genes measured.
Full finding, who was studied, and limits
Who: A human nerve-tumour cell line (IMR-32) grown in the laboratory, exposed to selank, GABA, the antipsychotic olanzapine and combinations.
Selank on its own did not change the activity of any of the 84 genes measured. When given with GABA, it almost completely cancelled the changes GABA caused. The authors concluded selank has no direct effect on these genes but may alter how GABA acts on its receptors.
Read with care: Cells in a dish. It tempers the gene-expression story: on its own, selank did nothing measurable here.
- Cell study2001
The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity
Enkephalins are the body's own opioid-like peptides.
Full finding, who was studied, and limits
Who: Blood plasma from patients with anxiety and phobic disorders, tested in the laboratory. The number of patients is not given in the abstract.
Enkephalins are the body's own opioid-like peptides. Patients with generalised anxiety had faster breakdown of enkephalin in their blood; patients with panic disorder and agoraphobia did not. Added to plasma in a test tube, selank slowed the breakdown of enkephalin, more strongly than two standard enzyme blockers. The authors proposed this as one way selank might reduce anxiety.
Read with care: A test-tube result. Slowing an enzyme in a sample of blood does not show the same happens in the brain of a living person.
Bulletin of experimental biology and medicine · pubmed.ncbi.nlm.nih.gov
Safety findings
- The FDA says compounded drugs containing selank acetate "may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities" and that it "lacks important information regarding any safety issues raised by selank acetate administered to humans". Source: fda.gov
- The published abstracts of the Russian patient studies do not list specific side effects of selank. The 2014 study named tolerability as an aim but its abstract reports no adverse-event findings. Source: pubmed.ncbi.nlm.nih.gov
- In the 2015 study, adding selank to phenazepam was reported to reduce phenazepam's side effects. This is a claim about the comparison drug, not evidence that selank itself has none. Source: pubmed.ncbi.nlm.nih.gov
- There are no long-term human safety data, and no registered trials. US reviewers in 2021 called selank poorly studied and said its potential for misuse should be evaluated. Source: pubmed.ncbi.nlm.nih.gov
2 more safety findings
- In a 2017 study in mouse embryonic stem cells, selank reduced the share of cells becoming GABA-producing neurons by about 61%; the authors still concluded the peptides tested showed no toxic effect. Its relevance to people is unknown. Source: pubmed.ncbi.nlm.nih.gov
- A Belgian medicines laboratory found selank in two seized, unidentified preparations in 2017 and 2018, and found it sold online as injectable powder and nasal sprays. Products bought this way have no regulatory quality control. Source: pubmed.ncbi.nlm.nih.gov
Rules and status
Not approved. Selank is not an FDA-approved medicine. It was nominated for pharmacy compounding, placed in the FDA's higher-risk Category 2, and the nomination was later withdrawn.
The full history, with dates
Selank acetate appears on the FDA page of bulk substances that may present significant safety risks (content current as of 22 April 2026) in the table of substances "nominated but withdrawn", described as substances previously in Category 2 whose nominators withdrew them. The FDA's stated concern: "Compounded drugs containing selank acetate may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities. FDA lacks important information regarding any safety issues raised by selank acetate administered to humans." Selank does not appear in any category of the FDA's 503A nominations list updated 14 May 2026. It was not on the agenda of the FDA Pharmacy Compounding Advisory Committee meeting of 23 and 24 July 2026 (Federal Register notice of 16 April 2026), and no FDA briefing document on selank was found. On 30 October 2026 HHS published notice of a draft, non-binding enforcement-discretion policy for compounding certain peptides (91 FR 68526); its Appendix A, read from an Internet Archive capture, names six peptides and selank is not one of them. Outside the US: Russian scientific papers call selank a drug, and Russian-language reference pages say it was registered in Russia in 2009 as nasal drops, but the Russian State Register of Medicines refused connections and its archived copy could not be opened, so this is not confirmed from a primary record. No EU authorisation was found, but the EMA website refused automated searches.
Source: fda.gov (source dated 2026-04-22)
In sport: Not named on the WADA Prohibited List for 2026 or 2027. Class S0 (non-approved substances, prohibited at all times) covers any substance not addressed elsewhere on the List "with no current approval by any governmental regulatory health authority for human therapeutic use"; the 2027 List adds peptides as an example, and WADA's explanatory note says an unnamed peptide may still be prohibited. If selank's reported Russian registration is current, the wording of S0 would not reach it; if it is not, S0 would. WADA's documents do not name selank or rule on its approval status, so they do not settle the question. Not named is not the same as permitted. WADA
Claims and what the evidence supports
| What people say | What the evidence supports |
|---|---|
| Selank is a proven anti-anxiety medicine. | The patient studies are three small Russian comparisons with benzodiazepines (60 to 70 patients each), with no placebo group and no description of blinding in their abstracts. They suggest an effect but cannot prove one. Source: pubmed.ncbi.nlm.nih.gov |
| It works as well as benzodiazepines without the side effects. | One study of 62 patients reported similar anxiety reduction to medazepam, but the abstracts of the patient studies give no detailed side-effect data for selank. The FDA says it lacks important safety information. Source: fda.gov |
| It acts on GABA receptors like a natural tranquilliser. | This rests on rat brain experiments and laboratory binding tests by the developers' network. In human nerve cells in a dish, selank alone changed none of the genes measured. Source: pubmed.ncbi.nlm.nih.gov |
| It is approved and legal everywhere because Russia approved it. | It is not approved in the United States, and its Russian registration could not be confirmed from the Russian register. The FDA lists it among peptides whose compounding nominations were withdrawn over safety concerns. Source: fda.gov |
| It is not banned in sport. | It is not named on the Prohibited List, but WADA warns that unnamed peptides may still be prohibited under S0. Whether S0 covers selank turns on its approval status, which WADA's documents do not settle. Source: wada-ama.org |
What a genuine lab report should show
- Identity by mass spectrometry: the measured mass should match 751.9 g/mol, the molecular weight of the free peptide Thr-Lys-Pro-Arg-Pro-Gly-Pro. Salt forms such as the acetate add mass, so the report should say which form was tested.
- Sequence confirmation, because selank shares its first four amino acids with tuftsin and its last three with the Pro-Gly-Pro fragment; short related peptides could be mistaken for it.
- Purity by HPLC, with peptide-related impurities and aggregates listed, since these are the FDA's stated concern.
- Tests for bacterial toxins (endotoxin) and microbial contamination.
- A lot number and test date that match the product, and a named laboratory.
What is not known
- Whether selank is currently registered as a medicine in Russia, and in what form. Russian-language pages say nasal drops registered in 2009, but the Russian State Register of Medicines refused connections and could not be checked.
- Whether WADA class S0 applies. That depends on whether the Russian registration counts as a current approval by a government health regulator. No WADA statement naming selank was found.
- The design details of the Russian patient studies (randomisation, blinding, treatment length, side effects). Only the abstracts were read; the full papers are in Russian.
- Whether any EU regulator has authorised it. The EMA website refused automated searches.
- A 2008 study of immune effects in patients with anxiety and fatigue disorders (PubMed 18577961) and a 2010 Russian clinical-pharmacology report were found but not used, because their abstracts gave too little detail.
- Whether the July 2026 FDA advisory committee or the FDA has said anything about selank since its nomination was withdrawn. Nothing was found.
Sources
All 25 sources
- PubChem: Selank, CID 11765600. pubchem.ncbi.nlm.nih.gov
- Seredenin et al. 1995, tuftsin and TP-7 in rats (Russian). pubmed.ncbi.nlm.nih.gov
- Czabak-Garbacz et al. 2006, TP-7 in rats (Poland). pubmed.ncbi.nlm.nih.gov
- Zozulya et al. 2001, selank and enkephalin-degrading enzymes. pubmed.ncbi.nlm.nih.gov
- Volkova et al. 2016, selank and GABA-related genes in rats (full text). frontiersin.org
- Filatova et al. 2017, GABA, selank and olanzapine in IMR-32 cells. pubmed.ncbi.nlm.nih.gov
- Vyunova et al. 2018, molecular aspects of selank activity. pubmed.ncbi.nlm.nih.gov
- Kasian et al. 2017, selank and diazepam in stressed rats. pubmed.ncbi.nlm.nih.gov
- Sokolov et al. 2002, selank and enkephalin-degrading enzymes in mice. pubmed.ncbi.nlm.nih.gov
- Zozulia et al. 2008, selank vs medazepam in 62 patients (Russian). pubmed.ncbi.nlm.nih.gov
- Medvedev et al. 2014, selank vs phenazepam in 60 patients (Russian). pubmed.ncbi.nlm.nih.gov
- Medvedev et al. 2015, phenazepam with or without selank in 70 patients (Russian). pubmed.ncbi.nlm.nih.gov
- Panikratova et al. 2020, brain scans in 52 healthy volunteers. pubmed.ncbi.nlm.nih.gov
- Doyno and White 2021, review of GABA-acting sedatives including selank. pubmed.ncbi.nlm.nih.gov
- Kobylyanskii et al. 2017, peptides in mouse embryonic stem cells. pubmed.ncbi.nlm.nih.gov
- Vanhee et al. 2020, research peptides in seized preparations (Belgium). pubmed.ncbi.nlm.nih.gov
- ClinicalTrials.gov search for selank (no studies, searched 18 November 2026). clinicaltrials.gov
- FDA: bulk drug substances that may present significant safety risks (current as of 22 April 2026). fda.gov
- FDA: 503A nominated substances by category, updated 14 May 2026. fda.gov
- Federal Register, 16 April 2026: Pharmacy Compounding Advisory Committee meeting notice. govinfo.gov
- Federal Register, 30 October 2026, 91 FR 68526: HHS draft enforcement-discretion policy notice. govinfo.gov
- HHS 503A peptide enforcement-discretion policy, Appendices A and B (read from an Internet Archive capture). hhs.gov
- WADA 2026 Prohibited List. wada-ama.org
- WADA 2027 Prohibited List. wada-ama.org
- WADA 2027 List: summary of major modifications and explanatory notes. wada-ama.org
Sources last checked 2026-11-18.
This page summarises published research and public records for education. It is not medical advice and it is not a guide to using any compound. If something here is wrong or out of date, tell us and we will correct it.